Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 19/20 | 0.72 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL275117 | 0.93 | NR1H4 (0.74) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL29880868 | 0.91 | NR1H4 (0.72) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL3731579 | 0.91 | NR1H4 (0.72) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL4305496 | 0.91 | NR1H4 (0.71) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL4304362 | 0.89 | NR1H4 (0.68) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL4304364 | 0.89 | NR1H4 (0.68) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL273271 | 0.89 | NR1H4 (0.75) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL274184 | 0.89 | NR1H4 (0.75) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL274159 | 0.88 | NR1H4 (0.69) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL4305816 | 0.87 | NR1H4 (0.70) | NR1H4ESR1NR3C1PGRNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595311-B2 | Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents | EXELIXIS, INC. (US) | 2009-09-29 | — | — | US | claimed |
| US-20050054634-A1 | Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents | AKARNA THERAPEUTICS, LTD. (GB) | 2005-03-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054634-A1 | Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents | GPR119, IRS1, INSR | NR1H4 75/4885ESR1 755/4885NR3C1 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.